Secondary prevention after intracerebral haemorrhage

Intracerebral haemorrhage (ICH) has high mortality in the acute phase and poor functional outcome in the majority of survivors. ICH recurrence is a major determinant of long‐term prognosis and is the most feared complication of antithrombotic treatment. On the other hand, ICH patients are at high risk of future ischaemic vascular events.

[1]  K. Chan,et al.  Blood Pressure Control Targets and Risk of Cardiovascular and Cerebrovascular Events After Intracerebral Hemorrhage , 2022, Stroke.

[2]  R. Krittayaphong,et al.  Improving risk prediction for death, stroke and bleeding in Asian patients with atrial fibrillation , 2022, European journal of clinical investigation.

[3]  J. Hallas,et al.  Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events , 2022, JAMA network open.

[4]  K. Sheth,et al.  Focused Update on Vascular Risk and Secondary Prevention in Survivors of Intracerebral Hemorrhage , 2022, Stroke.

[5]  S. Murthy,et al.  Cardiovascular Events After Intracerebral Hemorrhage , 2022, Stroke.

[6]  Michael T. Mullen,et al.  Review of Long-Term Blood Pressure Control After Intracerebral Hemorrhage: Challenges and Opportunities , 2022, Stroke.

[7]  J. Mocco,et al.  2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. , 2022, Stroke.

[8]  W. Cubała,et al.  Commentary concerning treatment of depression in patients with heart failure according to 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2022, European journal of preventive cardiology.

[9]  S. Greenberg,et al.  Lobar intracerebral hemorrhage and risk of subsequent uncontrolled blood pressure , 2022, European Stroke Journal.

[10]  A. Natale,et al.  Left atrial appendage closure in patients with intracranial hemorrhage , 2022, Journal of Interventional Cardiac Electrophysiology.

[11]  L. G. García Rodríguez,et al.  Higher Risk of Ischemic Stroke After an Intracerebral Hemorrhage Than in General Population: A Cohort Study From the United Kingdom. , 2021, Stroke.

[12]  A. Algra,et al.  Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial , 2021, The Lancet Neurology.

[13]  H. Jneid,et al.  Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation , 2021, Journal of the American Heart Association.

[14]  C. Sudlow,et al.  Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage , 2021, JAMA neurology.

[15]  G. Lip,et al.  Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. , 2021, The Lancet. Neurology.

[16]  L. Moscote-Salazar,et al.  Reader Response: Cause of Death in Spontaneous Intracerebral Hemorrhage Survivors: Multistate Longitudinal Study , 2021, Neurology.

[17]  L. Liberale,et al.  PCSK 9: A Link Between Inflammation and Atherosclerosis. , 2021, Current medicinal chemistry.

[18]  D. Werring,et al.  Diffusion-weighted imaging lesions and risk of recurrent stroke after intracerebral haemorrhage , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[19]  S. Gutnikov,et al.  Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies , 2021, The Lancet Neurology.

[20]  K. Chan,et al.  Impact of Uncontrolled Hypertension at 3 Months After Intracerebral Hemorrhage , 2021, Journal of the American Heart Association.

[21]  H. Kamel,et al.  Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies. , 2021, JAMA neurology.

[22]  Lin Liu,et al.  The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[23]  B. Wimmer,et al.  Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten‐year follow‐up , 2021, European journal of clinical investigation.

[24]  T. Chao,et al.  Non‐vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years , 2021, European journal of clinical investigation.

[25]  Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. , 2021, Circulation.

[26]  S. Greenberg,et al.  CT-Visible Convexity Subarachnoid Hemorrhage is Associated With Cortical Superficial Siderosis and Predicts Recurrent ICH , 2020, Neurology.

[27]  Steffen E. Petersen,et al.  2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2016, European journal of preventive cardiology.

[28]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[29]  H. Kamel,et al.  Cause of death in spontaneous intracerebral hemorrhage survivors , 2020, Neurology.

[30]  S. Greenberg,et al.  Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity. , 2020, JAMA neurology.

[31]  L. Räber,et al.  Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. , 2020, European journal of preventive cardiology.

[32]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.

[33]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.

[34]  Hong Wang,et al.  Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis , 2020, Stroke.

[35]  Yuting Liang,et al.  Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. , 2020, American journal of translational research.

[36]  G. Lip,et al.  Stroke prevention in elderly patients with non‐valvular atrial fibrillation in the BALKAN‐AF survey , 2020, European journal of clinical investigation.

[37]  A. Camm,et al.  EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[38]  K. Shimada,et al.  Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. , 2019, JAMA neurology.

[39]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[40]  A. Lichtenstein,et al.  Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage , 2019, Neurology.

[41]  C. Chiang,et al.  Does statin increase the risk of intracerebral hemorrhage in stroke survivors? A meta-analysis and trial sequential analysis , 2019, Therapeutic advances in neurological disorders.

[42]  R. Starling,et al.  Reversal and Resumption of Antithrombotic Therapy in LVAD-Associated Intracranial Hemorrhage. , 2019, The Annals of thoracic surgery.

[43]  Ashutosh Kumar Singh,et al.  Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial , 2019, Lancet.

[44]  D. Leys,et al.  Five-Year Risk of Major Ischemic and Hemorrhagic Events After Intracerebral Hemorrhage , 2019, Stroke.

[45]  B. Jahromi,et al.  Management and outcome of intracranial hemorrhage in patients with left ventricular assist devices , 2019, Journal of neurosurgery.

[46]  S. Greenberg,et al.  Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: Large prospective cohort and preliminary meta-analysis , 2019, International journal of stroke : official journal of the International Stroke Society.

[47]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[48]  J. Versmissen,et al.  No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[49]  M. Sabatine.  PCSK9 inhibitors: clinical evidence and implementation , 2018, Nature Reviews Cardiology.

[50]  G. Fink,et al.  Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves , 2018, European heart journal.

[51]  R. Calabró,et al.  Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy) , 2018, Thrombosis and Haemostasis.

[52]  Y. Liu,et al.  Resumption of antiplatelet therapy in patients with primary intracranial hemorrhage-benefits and risks: A meta-analysis of cohort studies , 2018, Journal of the Neurological Sciences.

[53]  H. Kamel,et al.  Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage , 2017, Annals of neurology.

[54]  Eric E. Smith,et al.  Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds , 2017, Neurology.

[55]  M. Rosenqvist,et al.  Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[56]  F. Montecucco,et al.  Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes. , 2017, Current medicinal chemistry.

[57]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[58]  K. Asplund,et al.  Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation , 2017, Stroke.

[59]  G. Lip,et al.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis , 2017, Stroke.

[60]  R. Lewis,et al.  Confounding by Indication in Clinical Research. , 2016, JAMA.

[61]  Ming-Tsang Wu,et al.  Statin use after intracerebral hemorrhage: a 10‐year nationwide cohort study , 2016, Brain and behavior.

[62]  E. Matteson,et al.  Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies , 2016, Stroke.

[63]  S. Greenberg,et al.  Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. , 2015, JAMA.

[64]  S. Greenberg,et al.  APOE ε4 and lipid levels affect risk of recurrent nonlobar intracerebral hemorrhage , 2015, Neurology.

[65]  V. Falk,et al.  Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. , 2015, International journal of cardiology.

[66]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[67]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[68]  Andrew E Moran,et al.  Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet. Global health.

[69]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[70]  Eric E. Smith,et al.  Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy , 2010, Neurology.

[71]  Ale Algra,et al.  Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis , 2010, The Lancet Neurology.

[72]  M. Woodward,et al.  Effects of Perindopril-Based Lowering of Blood Pressure on Intracerebral Hemorrhage Related to Amyloid Angiopathy: The PROGRESS Trial , 2010, Stroke.

[73]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[74]  M. Woodward,et al.  Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial , 2006, Journal of hypertension.

[75]  V. Santinelli,et al.  Prevention of Atrial Fibrillation: , 2004, Journal of cardiovascular electrophysiology.

[76]  曲东锋.  Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .

[77]  M. Woodward,et al.  Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial , 2003, Stroke.